Glaucoma News and Research

Latest Glaucoma News and Research

Online patient support program for ADHD patients taking Vyvanse Capsules CII medication

Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced the re-launch of FOCUS (http://www.vyvanseFOCUS.com), a free, online patient support program for adults taking once-daily Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), and the only online, branded personalized patient support program providing tips and tools for adults diagnosed with ADHD taking a prescription medication.

11 Nov 2009

ISTA Pharmaceuticals presents additional data from its Bepreve Phase 3 clinical studies

ISTA Pharmaceuticals, Inc., today announced additional results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies. These results were presented in poster sessions at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Miami Beach, FL.

9 Nov 2009

Pediatrician recommends red reflex vision test for all newborns

With the number of premature births and medically fragile infants now increasing in the U.S., a basic eye exam, including a red reflex test, should be given to all children shortly after birth, reports Angela Buffenn, M.D., M.P.H., Director of the Orbit and Eye Movement Institute at The Vision Center of Childrens Hospital Los Angeles.

7 Nov 2009

Gonorrhea medication may help fight cancer

Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. The newest surprise discovered by researchers at the Johns Hopkins University School of Medicine is a gonorrhea medication that might help battle cancer.

6 Nov 2009

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

Inspire Pharmaceuticals, Inc. announced today financial results for the third quarter ended September 30, 2009, reporting a net loss of $8.5 million or ($0.12) per common share.

5 Nov 2009

IBN iCare to develop cutting-edge nanomaterials for ocular therapy

Marking a significant bench to bedside research milestone in Singapore, the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, and the National University Hospital (NUH) launched the IBN iCare and the NUH Eye Centre @ Biopolis at an official opening ceremony officiated by the Senior Minister of State for Trade and Industry and Education, S. Iswaran, at the Biopolis on Nov. 3, 2009.

4 Nov 2009

Multicenter study finds AMD patients can benefit from cataract surgery

This month's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy) reports on a national study that finds cataract surgery is likely to benefit patients with age-related macular degeneration (AMD) at all stages of the disease, on a clinical trial showing that the steroid triamcinolone may be effective in advanced diabetic macular edema (DME) patients when standard treatment fails, and on the public's use of two Academy-sponsored online eye health forums.

2 Nov 2009

Shire to present key data on ADHD treatments at national psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV- (guanfacine) Extended Release Tablets, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, and Daytrana- (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.

31 Oct 2009

Shire announces Phase IIIb study results of Daytrana

Shire plc, the global specialty biopharmaceutical company, today announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).

31 Oct 2009

Shire's ADHD treatment data to be presented at the Honolulu psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV(TM) (guanfacine) Extended Release Tablets, Vyvanse®( ) (lisdexamfetamine dimesylate) Capsules CII, and Daytrana®( ) (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.

30 Oct 2009

Allergan reports operating results for the third quarter of 2009

Allergan, Inc. today announced operating results for the quarter ended September 30, 2009. Allergan also announced that its Board of Directors has declared a third quarter dividend of $0.05 per share, payable on November 30, 2009 to stockholders of record on November 9, 2009.

29 Oct 2009

Promedior granted European Orphan Medicinal Product Designation for PRM-151

Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today that the European Commission has granted Orphan Medicinal Product Designation to its lead drug candidate PRM-151 for use in the prevention of scarring post glaucoma filtration surgery.

29 Oct 2009

Veterans with TBI vision loss have poor quality of life compared to civilian patients

Pan-American Association of Ophthalmology (PAAO) Joint Meeting, includes a Veterans Administration study that indicates that Iraq and Afghanistan veterans with vision loss from traumatic brain injury have significantly poorer quality of life than comparable civilian patients, and a Harvard doctor's insights on how to best evaluate and care for low-vision patients who experience vivid visual hallucinations due to Charles Bonnet syndrome.

28 Oct 2009

Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and nine months ended September 30, 2009.

27 Oct 2009

Some patients with AMD develop elevated pressure within the eye following anti-VEGF medications: Study

A first-time finding of intraocular pressure increases in patients with no personal or family history of glaucoma following anti-VEGF treatment for wet age-related macular degeneration (AMD), and a report on a simple, low-cost method that could revolutionize vision screening and treatment in developing countries, are highlights of today's Scientific Program of the 2009 Joint Meeting of the American Academy of Ophthalmology (AAO) and the Pan-American Association of Ophthalmology (PAAO).

27 Oct 2009

STAAR Surgical Company reports promising assessments from CAST

STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products today reported that the Collamer Accommodating Study Team (CAST) formed by the company in late 2008 has provided very promising initial patient vision assessments from the first phase of the project.

26 Oct 2009

AAO-PAAO meeting discusses tougher challenges of treating premature babies' vision

Highlights of today's Scientific Program of the 2009 American Academy of Ophthalmology (AAO) - Pan-American Association of Ophthalmology (PAAO) Joint Meeting include: John T. Flynn, MD, Columbia University School of Medicine, discussing the ever-tougher challenges Eye M.D.s face in caring for the vision of the tiniest premature babies; and a report by Bradford W. Lee, MD, Stanford University School of Medicine, on barriers to glaucoma follow-up as perceived by patients in an urban, culturally diverse clinic.

26 Oct 2009

Saving sight in premature babies: The past, present and future of ROP treatment

26 Oct 2009

AFER and Pfizer Ophthalmics initiate awards recognizing the achievements of Dr. Carl B. Camras

The ARVO Foundation for Eye Research (AFER) and Pfizer Ophthalmics are pleased to announce a series of awards named in honor of Carl B. Camras, MD. Up to three awards of $10,000 each will be presented annually for a period of 10 years to early career researchers.

24 Oct 2009

U.S. District Court rules in favor of Allergan in its patent infringement suit against Exela PharmSci

Allergan, Inc. announced today that the United States District Court for the District of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd. ("Exela"), Apotex, Inc. and Apotex Corp. ("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan’s drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. Specifically, after a trial in March of 2009, the Court ruled today that all five patents (U.S. Patent Nos. 6,627,210; 6,641,834; 6,673,337; 6,562,873; and 5,424,078) asserted by Allergan are valid and enforceable, that Apotex's proposed generic versions of ALPHAGAN® P 0.1% and 0.15% infringe each of the five patents, and that Exela's proposed generic version of ALPHAGAN® P 0.15% infringes U.S. Patent No. 6,641,834, which was the only patent asserted against it. Pursuant to the Hatch-Waxman Act, the United States Food and Drug Administration is required to delay approval of Defendants’ proposed generic products until the last to expire of the infringed patents, which is 2022.

24 Oct 2009

Glaucoma News and Research

Latest Glaucoma News and Research

Online patient support program for ADHD patients taking Vyvanse Capsules CII medication

ISTA Pharmaceuticals presents additional data from its Bepreve Phase 3 clinical studies

Pediatrician recommends red reflex vision test for all newborns

Gonorrhea medication may help fight cancer

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

IBN iCare to develop cutting-edge nanomaterials for ocular therapy

Multicenter study finds AMD patients can benefit from cataract surgery

Shire to present key data on ADHD treatments at national psychiatric meeting

Shire announces Phase IIIb study results of Daytrana

Shire's ADHD treatment data to be presented at the Honolulu psychiatric meeting

Allergan reports operating results for the third quarter of 2009

Promedior granted European Orphan Medicinal Product Designation for PRM-151

Veterans with TBI vision loss have poor quality of life compared to civilian patients

Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials

Some patients with AMD develop elevated pressure within the eye following anti-VEGF medications: Study

STAAR Surgical Company reports promising assessments from CAST

AAO-PAAO meeting discusses tougher challenges of treating premature babies' vision

Saving sight in premature babies: The past, present and future of ROP treatment

AFER and Pfizer Ophthalmics initiate awards recognizing the achievements of Dr. Carl B. Camras

U.S. District Court rules in favor of Allergan in its patent infringement suit against Exela PharmSci

Innovation in neuroscience drug discovery - eBook eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Glaucoma News and Research

Latest Glaucoma News and Research

Innovation in neuroscience drug discovery - eBook eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in